Innate Pharma reports full year 2025 financial results and business update
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for i...
Publisher
France
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for i...
Source route
Continue on innate-pharma.com
Leave the platform to read the original full article on the publisher site.
Source: Innate Pharma (IR)
Scope: Industry
Related coverage
More related coverage
Mar 27, 2026Press releaseNovartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
Mar 23, 2026Press releaseNovartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Mar 20, 2026Press releaseNovartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summ...